The CooperCOO +3.13%84 5-Year Yield-on-Cost % is 0.00 as of Jul. 05, 2026. GuruFocus rates COO with a GF Score™ of 84/100 and a GF Value™ of $101.02 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 328 Medical Devices & Instruments companies, The Cooper ranks worse than 304877.74% on this metric.
The Cooper's yield on cost for the quarter that ended in Apr. 2026 was 0.00.
The historical rank and industry rank for The Cooper's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 13 years, The Cooper's highest Yield on Cost was 0.04. The lowest was 0.01. And the median was 0.02.
COO's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.325 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
The Cooper (NAS:COO) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
The Cooper 5-Year Yield-on-Cost % Related Terms
COO vs SOLV, ALGN, BAX: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, The Cooper's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where The Cooper's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of The Cooper is calculated as
The Cooper (COO) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 05, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on The Cooper and its competitors. Over the past decade, The Cooper's 5-Year Yield-on-Cost % has ranged from 0.01 to 0.04. According to the industry distribution chart, The Cooper ranks #999999 out of 328 companies in the Medical Devices & Instruments industry.
Is The Cooper's 5-Year Yield-on-Cost % too high?
The Cooper's current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.04. Based on the distribution chart, The Cooper ranks #999999 out of 328 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, The Cooper has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's 5-Year Yield-on-Cost % compare to SOLV and ALGN?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #999999 out of 328 companies for 5-Year Yield-on-Cost %. This places The Cooper in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.33. Historically, The Cooper's own 5-Year Yield-on-Cost % has ranged from 0.01 to 0.04 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.33, based on 328 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on The Cooper and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Modestly Undervalued. The stock's GF Value™ is $101.02, compared to a current price of $74.20 — trading 26.5% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. The Cooper's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For The Cooper (COO), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $74.20 is trading 26.5% below its estimated GF Value™ of $101.02.
GuruFocus considers The Cooper to be Modestly Undervalued.
Key valuation signals for COO:
5-Year Yield-on-Cost %: 0.00
GF Value™: $101.02 vs. price of $74.20 (26.5% below fair value)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
84GF Score
Get the complete analysis for COO
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 